{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:14:04Z","timestamp":1765898044745,"version":"3.48.0"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the real\u2010world effectiveness of octocog alfa (BAY 81\u20108973; Kovaltry) in people with haemophilia A (PwHA), including under\u2010represented subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed the American Thrombosis and Hemostasis Network (ATHN) dataset to identify the characteristics, treatment\/clinical histories and annualised bleeding rates (ABRs) of PwHA receiving prophylactic or on\u2010demand octocog alfa. Subgroup analyses included females and those switching to octocog alfa. Data are reported descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 270 PwHA treated with octocog alfa with available bleeding rate data between 1 January 2010 and 31 October 2020, mean (standard deviation) total ABRs were low (0.59 [2.22]) and\u2009&gt;\u200970% of those treated for &gt;\u200912\u2009months had 0 bleeds. At the second data cutoff (30 April 2022;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009354), subgroups who switched to octocog alfa from previous treatment had low mean total ABRs after switching, including adolescents (0.83;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), and those previously receiving emicizumab (0.17;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917). In females, 10\/11 reported 0 bleeds, and of those with joint range of motion data available (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), 100% had values \u2265\u200910% below the normal range in \u2265\u20092 joints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PwHA treated with octocog alfa in the ATHNdataset, including important subgroups, reported a low number of bleeds; thus, octocog alfa offers an effective therapeutic option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70016","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:55:31Z","timestamp":1754546131000},"page":"484-492","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Octocog Alfa (\n                    <scp>BAY<\/scp>\n                    81\u20108973) to Treat People With Haemophilia A Enrolled in the\n                    <scp>ATHNdataset<\/scp>\n                    , Including Under\u2010Represented Subgroups"],"prefix":"10.1111","volume":"115","author":[{"given":"Martin","family":"Chandler","sequence":"first","affiliation":[{"name":"American Thrombosis &amp; Hemostasis Network  Rochester New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Moulton","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC  Whippany New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Charafi","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC  Whippany New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Charlet","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC  Whippany New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Recht","sequence":"additional","affiliation":[{"name":"American Thrombosis &amp; Hemostasis Network  Rochester New York USA"},{"name":"Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14186"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14403"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14232"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12468"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15397"},{"key":"e_1_2_10_10_1","unstructured":"European Medicines Agency \u201cKovaltry. Summary of Prescribing Characteristics \u201d(2022) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kovaltry\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_11_1","unstructured":"Bayer HealthCare \u201cKovaltry. Prescribing Information \u201d(2022) https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Kovaltry_PI.pdf."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12952"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12866"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12839"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12828"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123434"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01676-w"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13876"},{"key":"e_1_2_10_19_1","unstructured":"American Thrombosis & Hemostasis Network \u201cAdvancing Research With Better Data Through the ATHNdataset \u201d(2024) https:\/\/athn.org\/what\u2010we\u2010do\/national\u2010projects\/athndataset.html."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1457"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02399.x"},{"key":"e_1_2_10_22_1","unstructured":"Centers for Disease Control and Prevention \u201cNormal Joint Range of Motion Study [Online] \u201d(2024) https:\/\/archive.cdc.gov\/#\/details?q=https:\/\/www.cdc.gov\/ncbddd\/jointrom\/index.html&start=0&rows=10&url=https:\/\/www.cdc.gov\/ncbddd\/jointrom\/index.html."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.15256\/joc.2011.1.2"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23754"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"e_1_2_10_26_1","unstructured":"U. S. Food and Drug Administration \u201cHEMLIBRA Highlights of Prescribing Information \u201d(2022) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761083s015lbl.pdf."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T14:46:48Z","timestamp":1765896408000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/ejh.70016"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70016","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"2025-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}